Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.390
-0.070 (-1.57%)
Dec 20, 2024, 4:00 PM EST - Market closed
Radiopharm Theranostics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Operating Revenue | 0.3 | 0.3 | 0.29 | - | - |
| Other Revenue | 1.66 | 1.66 | 5.92 | - | - |
| Revenue | 1.96 | 1.96 | 6.21 | - | - |
| Revenue Growth (YoY) | -68.46% | -68.46% | - | - | - |
| Cost of Revenue | 21.61 | 21.61 | 19.53 | 7.49 | - |
| Gross Profit | -19.65 | -19.65 | -13.32 | -7.49 | - |
| Selling, General & Admin | 13.04 | 13.04 | 12.23 | 7.64 | 0.3 |
| Operating Expenses | 15.68 | 15.68 | 15.27 | 12.44 | 1.16 |
| Operating Income | -35.33 | -35.33 | -28.59 | -19.93 | -1.16 |
| Interest Expense | -0.64 | -0.64 | -0.09 | -9.35 | - |
| Interest & Investment Income | 0.05 | 0.05 | 0.15 | 0.01 | - |
| Currency Exchange Gain (Loss) | 0.09 | 0.09 | -0.26 | -1.11 | -0 |
| EBT Excluding Unusual Items | -35.83 | -35.83 | -28.79 | -30.38 | -1.16 |
| Gain (Loss) on Sale of Assets | -1.69 | -1.69 | - | - | - |
| Asset Writedown | -1.48 | -1.48 | -3.1 | - | - |
| Other Unusual Items | -8.86 | -8.86 | -2.68 | - | - |
| Pretax Income | -47.85 | -47.85 | -34.57 | -30.38 | -1.16 |
| Income Tax Expense | 0.1 | 0.1 | 0.04 | 0.04 | - |
| Net Income | -47.95 | -47.95 | -34.61 | -30.42 | -1.16 |
| Net Income to Common | -47.95 | -47.95 | -34.61 | -30.42 | -1.16 |
| Shares Outstanding (Basic) | 386 | 386 | 306 | 181 | - |
| Shares Outstanding (Diluted) | 386 | 386 | 306 | 181 | - |
| Shares Change (YoY) | 26.36% | 26.36% | 68.74% | - | - |
| EPS (Basic) | -0.12 | -0.12 | -0.11 | -0.17 | - |
| EPS (Diluted) | -0.12 | -0.12 | -0.11 | -0.17 | - |
| Free Cash Flow | -22.98 | -22.98 | -23.25 | -9.91 | -0.08 |
| Free Cash Flow Per Share | -0.06 | -0.06 | -0.08 | -0.05 | - |
| Gross Margin | - | - | -214.52% | - | - |
| Operating Margin | -1803.82% | -1803.82% | -460.41% | - | - |
| Profit Margin | -2448.23% | -2448.23% | -557.36% | - | - |
| Free Cash Flow Margin | -1173.12% | -1173.12% | -374.36% | - | - |
| EBITDA | -32.2 | -32.2 | -25.29 | -16.94 | - |
| D&A For EBITDA | 3.13 | 3.13 | 3.3 | 2.98 | - |
| EBIT | -35.33 | -35.33 | -28.59 | -19.93 | -1.16 |
Source: S&P Capital IQ. Standard template.
Financial Sources.